Funovics J M, Karner J, Pratschner T, Fritsch A
Surg. Dept. I, Univ. Vienna, General Hospital.
Hepatogastroenterology. 1989 Dec;36(6):450-5.
Between 1965 and 1987, 783 patients were treated for ductal adenocarcinoma. Of these, 59% had carcinoma of the pancreatic head and 22% presented with carcinoma of the body or tail. In 19% of the cases the entire organ was involved. Two hundred and twenty-six patients (25.5%) underwent exploratory laparotomy; 420 patients (55%) had palliative operations, and 137 (18.5%) were resected for cure. In the past 3 years the resection rate increased from an original 18.5% to 28% (43 resective procedures in 153 patients). In 37 of the 137 patients (28%) surgery had to be extended to the portal vein, the superior mesenteric vein, the kidneys, adrenals, colon, stomach, liver and lymph nodes to ensure adequate radicality. At the same time in-hospital mortality (including deaths after extended procedures) dropped to 7%. Of the 137 patients resected for cure, 47% were alive at 1 year, 22% at 2 years, 12% at 3 years, 7% at 4 years, and 5% at 5 years. Mean survival time excluding in-hospital deaths was 18.65 months. In the first 15 months after surgery there was no difference in survival between standard resections and extended resections. Patients undergoing partial pancreaticoduodenectomy fared significantly better (p less than 0.01; Mantel) than those who had total resections, in terms of both median survival (10.8 versus 5.4 months) and mean survival (19.0 versus 7.82 months).(ABSTRACT TRUNCATED AT 250 WORDS)
1965年至1987年间,783例患者接受了导管腺癌治疗。其中,59%为胰头癌,22%为胰体或胰尾癌。19%的病例整个器官受累。226例患者(25.5%)接受了剖腹探查术;420例患者(55%)接受了姑息性手术,137例(18.5%)接受了根治性切除。在过去3年中,切除率从最初的18.5%提高到了28%(153例患者中有43例进行了切除手术)。137例患者中有37例(28%)手术不得不扩大到门静脉、肠系膜上静脉、肾脏、肾上腺、结肠、胃、肝脏和淋巴结,以确保足够的根治性。与此同时,住院死亡率(包括扩大手术后的死亡)降至7%。在137例接受根治性切除的患者中,1年生存率为47%,2年生存率为22%,3年生存率为12%,4年生存率为7%,5年生存率为5%。排除住院死亡后的平均生存时间为18.65个月。手术后的前15个月,标准切除和扩大切除的生存率没有差异。接受部分胰十二指肠切除术的患者在中位生存期(10.8个月对5.4个月)和平均生存期(19.0个月对7.82个月)方面均明显优于接受全切除术的患者(p<0.01;Mantel检验)。(摘要截断于250字)